Pompe disease market worth to approach $1 billion by 2027, says report

A report has predicted a significant growth in the Pompe disease market size due to growing general physician awareness and improvement in diagnosis models, according to GlobalData, a leading data and analytics company.

Like most rare diseases, the Pompe disease market is incredibly niche, comprising of a single enzyme replacement therapy by Sanofi (Euronext: SAN) unit Sanofi Genzyme. The market’s pipeline is also sparse of novel therapies, most of which are in preclinical stages of development.

According to the report, entitled Pompe Disease: Opportunity Analysis and Forecasts to 2027, the pipeline in this therapy area consists of seven products across all stages of clinical development across the eight major markets.